Differential Diagnosis

Importance of Early Diagnosis of HS

Many patients experience significant delays in receiving a diagnosis of hidradenitis suppurativa (HS). This is often due to1,2:

  • Patients waiting to seek medical attention until later stages of disease
  • HS being mistaken for other conditions with similar symptoms

Prompt, accurate diagnosis can aid in the initiation of proper treatment and help prevent the progression to more debilitating stages.1,3

HS Diagnosis Statistics

Time until diagnosis icon

Patients experience a significant delay in receiving an HS diagnosis

Average time to diagnosis is 7-10 years4

Misdiagnosis icon

Patients are initially misdiagnosed

Patients may have more than 17 visits before receiving a correct diagnosis5

Clinician icon

Patients may visit multiple clinicians before receiving a diagnosis

4 to 5 physicians may be seen prior to an accurate HS diagnosis4-6

Symptom icon

Patients may initially think symptoms are temporary and not too bothersome

Patients wait an average of 2.3 years before first presenting to a physician6

Differential Diagnoses of HS

Follicular pyodermas (carbuncles, furuncles, boils)7-9

IMPORTANT SAFETY INFORMATION

What is the most important safety information I should know about VYALEV? Do not take VYALEV if you currently take or have recently taken (within 2 weeks) a medication for depression called a non-selective monoamine oxidase (MAO) inhibitor. Ask your healthcare provider or pharmacist if you are not sure if you take an MAO inhibitor. Tell you healthcare...

USE

VYALEV is a prescription medicine used for treatment of advanced Parkinson's disease. VYALEV contains 2 medicines, foscarbidopa and foslevodopa.

IMPORTANT SAFETY INFORMATION

What is the most important safety information I should know about VYALEV? Do not take VYALEV if you currently...

USE

VYALEV is a prescription medicine used for treatment of advanced Parkinson's disease. VYALEV contains 2 medicines, foscarbidopa and foslevodopa.

IMPORTANT SAFETY INFORMATION

What is the most important safety information I should know about VYALEV? Do not take VYALEV if you currently take or have recently taken (within 2 weeks) a medication for depression called a non-selective monoamine oxidase (MAO) inhibitor. Ask your healthcare provider or pharmacist if you are not sure if you take an MAO inhibitor. Tell you healthcare...

USE

VYALEV is a prescription medicine used for treatment of advanced Parkinson's disease. VYALEV contains 2 medicines, foscarbidopa and foslevodopa.

IMPORTANT SAFETY INFORMATION

What is the most important safety information I should know about VYALEV? Do not take VYALEV if you currently...

USE

VYALEV is a prescription medicine used for treatment of advanced Parkinson's disease. VYALEV contains 2 medicines, foscarbidopa and foslevodopa.

Follicular pyodermas (carbuncles, furuncles,boils)

Boil

Differentiation: Unlike HS, which typically exhibits a chronic and recurrent course, follicular pyodermas are transient lesions that usually respond rapidly to appropriate antibiotic therapy. In addition, the follicular pyodermas do not cause the comedones, persistent sinus tracts, and hypertrophic scarring observed in HS.

Cutaneous Crohn’s disease7,10
Cutaneous Crohn's disease

Cutaneous Crohn's disease

Adapted with permission from Rice SA, Woo PN, El-Omar E, et al. BMC Res Notes. 2013.10

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Differentiation: “Knife-cut” ulcers and no blackheads; fistulas connect with the gastrointestinal tract; concurrent with gastrointestinal Crohn’s disease.

Acne, cystic acne7
Acne, cystic acne

Cystic acne

Differentiation: Distribution on the face, back, and upper chest, and include whiteheads. HS primarily involves the axillae, groin, buttocks, and inframammary folds. Additionally, HS typically involves more deep-seated lesions leading to sinus tracts and scarring.

Granuloma inguinale7
Granuloma inguinale

Granuloma inguinale

Differentiation: Red ulcers that bleed easily, granulation of tissue; has Donovan bodies (histology); infectious agent: Klebsiella granulomatis.

Lymphogranuloma venereum7
Lymphogranuloma venereum

Lymphogranuloma venereum

Differentiation: Bacterial etiology: Chlamydia trachomatis (serotype L1-L3)

Actinomycosis7
Actinomycosis

Actinomycosis

Differentiation: Bacterial infection caused by Actinomyces

Cutaneous tuberculosis7
Cutaneous tuberculosis

Tuberculosis verrucosa cutis

Differentiation: Bacterial infection caused by Mycobacterium

Other considerations11
Other considerations, for example, epidermoid or dermoid cyst, pilonidal cyst, erysipelas

Epidermoid cyst

  • Epidermoid or dermoid cyst12
  • Pilonidal cyst
  • Erysipelas

QUIZ: Make Your Diagnosis

Review the following 3 patient cases and determine the most likely diagnosis. Reference the HS diagnosis criteria to help inform your choices.

Choose your specialty:

Dermatology MD

Explore treatment options for HS.

View Treatments for HS »

Dermatology NP, PA

Explore treatment options for HS.

View Treatments for HS »

OB/GYN

Explore treatment options for HS.

View Treatments for HS »

PCP, Pediatrician

Learn about the role of systemic inflammation in HS.

Explore Causes of HS »

Partner with an HS specialist to co-manage HS.

Locate an HS Specialist »

Other Specialty

Learn about the role of systemic inflammation in HS.

Explore Causes of HS »

Partner with an HS specialist to co-manage HS.

Locate an HS Specialist »

What do you use to treat HS?

Select all that apply:

 

Review case studies of patients with HS.

View Case Studies »

Partner with an HS specialist to co-manage HS.

Locate an HS Specialist »

View ultrasound images of subdermal damage with HS.

See Progression of Disease »

Other Medical Treatments Content

Procedural treatments Content

Physician quote icon

“It’s critically important to diagnose HS early and intervene with medical therapies given the progressive, irreversible nature of the disease.”

- Dermatologist

REFERENCES

1. Micheletti RG. Natural history, presentation, and diagnosis of hidradenitis suppurativa. Semin Cutan Med Surg. 2014;33(suppl 3):S51-S53. 2. Jemec GBE. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164. 3. Kimball AB, Rahawi K, Duan Y, Alavi A, Okun MM. Impact of delayed diagnosis in patients with hidradenitis suppurativa (HS): real-world data from the UNITE HS registry. Poster presented at: Symposium on Hidradenitis Suppurativa Advances; November 1-3, 2019; Detroit, MI. 4. Garg A, Neuren E, Cha D, et al. Evaluating patients' unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366-376. 5. Alavi A, Lynde C, Alhusayen R, et al. Approach to the management of patients with hidradenitis suppurativa: a consensus document. J Cutan Med Surg. 2017;21(6):513-524. 6. Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546-1549. 7. Saunte DML, Jemec GBE. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA. 2017;318(20):2019-2032. 8. Boils and carbuncles. Mayo Clinic. Updated September 11, 2019. Accessed January 29, 2020. https://www.mayoclinic.org/diseases-conditions/boils-and-carbuncles/symptoms-causes/syc-20353770. 9. Collier F, Smith RC, Morton CA. Diagnosis and management of hidradenitis suppurativa. BMJ. 2013;346:f2121. 10. Rice SA, Woo PN, El-Omar E, Keenan RA, Ormerod AD. Topical tacrolimus 0.1% ointment for treatment of cutaneous Crohn's disease. BMC Res Notes. 2013;6:19. 11. Shah N. Hidradenitis suppurativa: a treatment challenge. Am Fam Physician. 2005;72(8):1547-1552. 12. Dermnet Skin Disease Atlas. Accessed June 18, 2019. http://www.dermnet.com/images/Epidermal-Cyst/picture/16454.